Contraindications in personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and pregnancy or breastfeeding
A serious warning on risk of thyroid C-cell tumours
Other relevant warnings and precautions relating to intramuscular administered, pancreatitis, hypoglycemia with concomitant use of insulin secretagogues or insulin, use with other
incretin drugs, hypersensitivity, diabetic retinopathy (in patients with history of disease monitor for progression), renal impairment (severe GI adverse reactions warrant monitoring of
renal function; use in end-stage disease), CV effects (increased heart rate; PR interval prolongation), and hepatic insufficiency
Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions
Quebec (RAMQ*) Exceptional Medication: For the treatment of type-2 diabetic persons, in association with metformin, where a sulfonylurea is contraindicated, not tolerated or ineffective. Authorization is given for a weekly maximum dose of 1 mg. Ineffectiveness means the non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient.
* Official mark of the Régie de l’assurance maladie du Québec.